About: http://data.cimple.eu/news-article/86b39f82c549c14e6d329aaa7f2eef04f323da9a6d1bc7831e380c63

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: http://data.cimple.eu/news-article/86b39f82c549c14e6d329aaa7f2eef04f323da9a6d1bc7831e380c63 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

Attributes	Values
rdf:type	schema:NewsArticle
schema:articleBody	Johnson & Johnson said on Monday it had selected a lead candidate vaccine for the new coronavirus that would move to human trials by September and could be ready for emergency use by early next year. The pharmaceutical company has signed an agreement with the US government's Biomedical Advanced Research and Development Authority to invest $1 billion in the effort, it said in a statement. J&J began working on the investigational vaccine, Ad26 SARS-CoV-2 in January using the same technology it used to develop a candidate vaccine for Ebola. It uses a deactivated version of the virus to try to trigger a human immune response. The company said it was expanding its global manufacturing capacity both in the US and in other countries, to help it supply more than a billion doses of its vaccine around the world. CEO Alex Gorsky said the company was "well positioned through our combination of scientific expertise, operational scale and financial strength to bring our resources in collaboration with others to accelerate the fight against this pandemic." J&J is also working on antiviral treatments against the coronavirus. Separately, the US pharmaceutical Moderna has already moved into human trials for its vaccine candidate, as has China's CanSinoBIO. There are currently no approved vaccines or treatments for the disease. Several treatments are being investigated, including the antiviral remdesivir and antimalarial drugs chloroquine and hydroxychloroquine, but it is not yet clear whether they add anything to standard care. ia/ft
schema:headline	Human testing for Johnson & Johnson coronavirus vaccine this fall
schema:mentions	Antimalarial medication Immune response Antiviral drug Remdesivir Pharmaceutical industry Johnson & Johnson Chloroquine Ebola virus disease Ia (cuneiform) Hydroxychloroquine Chief executive officer Pandemic Vaccine China Severe acute respiratory syndrome coronavirus 2 Alex Gorsky
schema:author	http://data.cimple.eu/organization/1f0054d541e000623a2c1e561a247c073ef6328e8be9ffafda7b3fcd
schema:datePublished	2020-03-30 (xsd:date)
http://data.cimple...sPoliticalLeaning	other political leaning
http://data.cimple...logy#hasSentiment	neutral sentiment
http://data.cimple...readability_score	86 (xsd:integer)
http://data.cimple...tology#hasEmotion	happiness

Faceted Search & Find service v1.16.115 as of Oct 09 2023

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 5 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software